Identifiants & Marche
Ticker
NRSNW
ISIN
IL0011811630
CIK
0001875091
Bourse
NASDAQ
Devise
USD
Entreprise
Pays
IL
Siege
N/A
Fondee
N/A
Description
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.